Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, ...

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...

Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...

As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...

Paris: Sanofi has announced the appointment of Jean-Paul Kress as an Independent Director, effective January 1, 2025.

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major ...